Difference between revisions of "Tamibarotene (Amnoid)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
Line 15: | Line 15: | ||
[[Category:Acute promyelocytic leukemia medications]] | [[Category:Acute promyelocytic leukemia medications]] | ||
− | [[Category:PMDA approved | + | [[Category:PMDA approved drugs]] |
Revision as of 02:40, 12 August 2018
Mechanism of action
From the NCI Drug Dictionary: An orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity. As a specific retinoic acid receptor (RAR) alpha/beta agonist, tamibarotene is approximately ten times more potent than ATRA in inducing cell differentiation and apoptosis in HL-60 (human promyelocytic leukemia) cell lines in vitro. Due to a lower affinity for cellular retinoic acid binding protein (CRABP), tamibarotene may show sustained plasma levels compared to ATRA. In addition, this agent may exhibit a lower toxicity profile than ATRA, in part, due to the lack of affinity for the RAR-gamma receptor, the major retinoic acid receptor in the dermal epithelium.
Diseases for which it is used
Also known as
- Brand names: Amnoid, Amnolake